News | February 27, 2025
Senores Pharmaceuticals begins operations at greenfield API facility
This is Senores' second API manufacturing facility adding significantly to the existing API manufacturing capabilities.
This is Senores' second API manufacturing facility adding significantly to the existing API manufacturing capabilities.
The Alathur facility specializes in the production of Cephalosporin antibiotics
This innovative formulation combines cutting-edge ingredients is a first of its kind in India to have a Duo-Lipo technology
Pascal Villemagne has announced his intent to step down at the end of March 2025, to take on a new challenge in his professional career.
The company is committed to revolutionizing API development by advancing synthesis and analytical processes that enhance quality and impact lives
EBITDA margins expand to 31.3%
The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space
The company ensures a reliable and strong portfolio at competitive prices without compromising on excellent quality
The site’s GMP Certification has been successfully renewed
Increases speed to market for drug developers working on nucleic acid therapeutics
Subscribe To Our Newsletter & Stay Updated
